Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL04
- Pharmacological subgroupL04A
- Chemical subgroupL04AASelective immunosuppressants
- Chemical substanceL04AA24Abatacept
Where it is registered
Each register and historical list with its number of registrations and a few of them.
United States
FDA · 5 registrations
- Orencia250MG · injectable · Bristol Myers Squibb
- Orencia125MG/ML · Injection · Bristol-Myers Squibb Company
- Orencia50MG/0.4ML · Injection · Bristol-Myers Squibb Company
- Orencia87.5MG/0.7ML · Injection · Bristol-Myers Squibb Company
Netherlands
CBG-MEB · 4 registrations
At a glance
- ATC code
- L04AA24
- Registers
- 7
- Historical lists
- 2
- Registrations
- 23
- With their own page
- 17
- Companies
- 7
All medicines with Abatacept
Human medicines from every register that match Abatacept by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
23 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Orencia | United States | 250MG | injectable | Marketed | Bristol Myers Squibb |
| Orencia | United States | 125MG/ML | Injection | Marketed | Bristol-Myers Squibb Company |
| Orencia | United States | 50MG/0.4ML | Injection | Marketed | Bristol-Myers Squibb Company |
| Orencia | United States | 87.5MG/0.7ML | Injection | Marketed | Bristol-Myers Squibb Company |
| Orencia | United States | 125MG/ML | Injection | Marketed | Bristol-Myers Squibb Company |
| Orencia | European Union | Authorised | Bristol-Myers Squibb Pharma EEIG | ||
| ORENCIA 125 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA | Spain | 125,875 mg | solución inyectable en jeringa precargada | Marketed | Bristol-Myers Squibb Pharma Eeig |
| ORENCIA 125 mg SOLUCION INYECTABLE EN PLUMA PRECARGADA | Spain | 125,875 mg | solución inyectable en pluma precargada | Marketed | Bristol-Myers Squibb Pharma Eeig |
| ORENCIA 250 mg POLVO PARA CONCENTRADO PARA SOL. PARA PERFUSION | Spain | 250 mg | concentrado para solución para perfusión | Marketed | Bristol-Myers Squibb Pharma Eeig |
| ORENCIA 125 mg oplossing voor injectie in een voorgevulde spuit | Netherlands | Oplossing voor injectie | Authorised | Bristol-Myers Squibb Pharma EEIG | |
| ORENCIA 250 mg poeder voor concentraat voor oplossing voor infusie. | Netherlands | Authorised | Bristol-Myers Squibb Pharma EEIG | ||
| ORENCIA 50 mg oplossing voor injectie in een voorgevulde spuit | Netherlands | Oplossing voor injectie | Authorised | Bristol-Myers Squibb Pharma EEIG | |
| ORENCIA 87,5 mg oplossing voor injectie in een voorgevulde spuit | Netherlands | Oplossing voor injectie | Authorised | Bristol-Myers Squibb Pharma EEIG | |
| Orencia | Canada | 250 MG / VIAL | Powder For Solution | Marketed | Bristol-Myers Squibb Canada |
| Orencia | Canada | 125 MG / ML | Solution | Marketed | Bristol-Myers Squibb Canada |
| Orencia | Brazil | Authorised | Bristol-Myers Squibb Farmacêutica Ltda | ||
| Orencia | Croatia | Authorised | |||
| ORENCIA 125MG Solution for injection in pre-filled syringe | Saudi Arabia | Authorised | BRISTOL-MYERS SQUIBB HOLDINGS PHARMA, Ltd. LIABBILITY COMPANY | ||
| Orencia 250MG Powder for Solution for Infusion | Saudi Arabia | Authorised | Bristol-Myers Squibb | ||
| Orencia | Canada | 125 MG / ML | Solution | Cancelled | Bristol-Myers Squibb Canada |
| ORENCIA 125 mg | Romania | 125mg | sol inj. in stilou injector (pen) preumplut | Status unknown | Bristol-Myers Squibb Pharma Eeig |
| ORENCIA 125 mg/ml | Romania | 125mg/ml | sol inj. in seringa pre-umpluta | Status unknown | Bristol-Myers Squibb Pharma Eeig |
| ORENCIA 250 mg | Romania | 250mg | pulb. pt.conc. pt.sol. perf. | Status unknown | Bristol-Myers Squibb Pharma Eeig |